Bing H Yu

US Patent:

20120220576, Aug 30, 2012

Filed:

Jan 30, 2012

Appl. No.:

13/361365

Inventors:

Branko RADETICH - Boston MA, US
Bing YU - Cambridge MA, US
Yanyi ZHU - Acton MA, US

International Classification:

A61K 31/5377
C07D 487/04
A61P 25/28
A61K 31/5386
C07D 491/08
A61P 35/00
C07D 473/16
C07D 498/08

US Classification:

5142305, 544 81, 5142325, 544 80, 544 73, 544118, 5142342

Abstract:

The invention relates to novel heterocyclic compounds of the formulain which all of the variables are as defined in the specification, to their preparation, to their medical use, in particular to their use in the treatment of cancer and neurodegenerative disorders, and to medicaments comprising them.

US Patent:

20230091510, Mar 23, 2023

Filed:

May 19, 2020

Appl. No.:

17/612280

Inventors:

- Basel, CH
Katsumasa NAKAJIMA - Winchester MA, US
Matthew T. BURGER - Belmont MA, US
Joseph Anthony D'ALESSIO - Boston MA, US
Eric MCNEILL - Arlington MA, US
Mark G, PALMERO - Ridge NH, US
Bing YU - Belmont MA, US
Qiang ZHANG - East Brunswick NJ, US

International Classification:

A61K 47/68
A61K 47/54
A61K 47/60
A61K 47/61
A61P 35/00
C07K 16/28
C07K 5/062

Abstract:

Provided herein are linkers, linker-drug groups and anti-body-drug conjugates comprising hydrophilic groups.

US Patent:

20230092679, Mar 23, 2023

Filed:

May 19, 2020

Appl. No.:

17/613006

Inventors:

- Basel, CH
- Suresnes Cedex, FR
Frédéric Colland - Puiseux-en-France, FR
Marton Csekei - Dunakeszi, HU
Lea Delacour - Luxembourg, LU
Patrice Desos - Bois Colombes, FR
Olivier Geneste - Rueil-Malmaison, FR
Jean-Michel Henlin - Suresnes, FR
Vesela Kostova - Saint Cloud, FR
Andras Kotschy - Torokbalint, HU
Ana Leticia Maragno - Croissy-sur-Seine, FR
Eric McNeill - Arlington MA, US
Mark G. Palermo - Ringe NH, US
Francesca Rocchetti - Paris, FR
Jérôme Starck - Rueill-Malmaison, FR
Bing Yu - Belmont MA, US
Qiang Zhang - East Brunswick NJ, US
Ágnes Proszenyák - Budapest, HU
Szabolcs Sipos - Budapest, HU
Zhuoliang Chen - Belmont MA, US
Katsumasa Nakajima - Winchester MA, US
Joseph Anthony D'Alessio - Boston MA, US

International Classification:

A61K 47/68
A61K 47/65
A61K 31/505
A61P 35/00

Abstract:

Antibody-drug conjugates that bind to human oncology targets are disclosed. The antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising an Mcl-1 inhibitor drug moiety and methods of making same are also disclosed.

US Patent:

20230081720, Mar 16, 2023

Filed:

May 19, 2020

Appl. No.:

17/613020

Inventors:

- Basel, CH
- Suresnes Cedex, FR
Frédéric Colland - Puiseux-en-France, FR
Marton Csekei - Dunakeszi, HU
Lea Delacour - Luxembourg, LU
Patrice Desos - Bois Colombes, FR
Olivier Geneste - Rueil-Malmaison, FR
Jean-Michel Henlin - Suresnes, FR
Vesela Kostova - Saint Cloud, FR
Andras Kotschy - Torokbalint, HU
Ana Leticia Maragno - Croissy-sur-Seine, FR
Eric McNeill - Arlington MA, US
Mark G. Palermo - Ringe NH, US
Francesca Rocchetti - Paris, FR
Jérôme Starck - Rueill-Malmaison, FR
Bing Yu - Belmont MA, US
Qiang Zhang - East Brunswick NJ, US
Ágnes Proszenyák - Budapest, HU
Szabolcs Sipos - Budapest, HU
Zhuoliang Chen - Belmont MA, US
Katsumasa Nakajima - Winchester MA, US
Joseph Anthony D'Alessio - Boston MA, US
John William Blankenship - Acton MA, US

International Classification:

A61K 47/68

Abstract:

Anti-CD74 antibody-drug conjugates are disclosed. The anti-CD74 antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety and an anti-CD74 antibody or antigen-binding fragment thereof that binds an antigen target, e.g., an antigen expressed on a tumor or other cancer cell. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising an Mcl-1 inhibitor drug moiety and methods of making same are also disclosed.

US Patent:

20210300919, Sep 30, 2021

Filed:

Dec 22, 2020

Appl. No.:

17/130374

Inventors:

- Basel, CH
Jorge Garcia FORTANET - Wilmington MA, US
Rajesh KARKI - Quincy MA, US
Matthew J. LAMARCHE - Reading MA, US
Dyuti MAJUMDAR - Cambridge MA, US
Lawrence Blas PEREZ - Silver Spring MD, US
Martin SENDZIK - Belmont MA, US
Troy Douglas SMITH - Nashua NH, US
Fan YANG - West Roxbury MA, US
Bing YU - Belmont MA, US

International Classification:

C07D 471/04
C07D 513/04
C07D 495/04
C07D 487/04
C07D 401/14
C07D 519/00
C07D 455/02
C07D 403/14
A61P 35/00

Abstract:

The present invention relates to compounds of formula I:

US Patent:

20200002330, Jan 2, 2020

Filed:

Jun 12, 2017

Appl. No.:

16/309076

Inventors:

- Basel, CH
Jorge Garcia FORTANET - Wilmington MA, US
Rajesh KARKI - Quincy MA, US
Matthew J. LAMARCHE - Reading MA, US
Dyuti MAJUMDAR - Cambridge MA, US
Lawrence Blas PEREZ - Silver Spring MD, US
Martin SENDZIK - Belmont MA, US
Troy Douglas SMITH - Nashua NH, US
Fan YANG - West Roxbury MA, US
Bing YU - Belmont MA, US

Assignee:

Novartis AG - Basel

International Classification:

C07D 471/04
C07D 513/04
C07D 495/04
C07D 487/04
C07D 403/14
C07D 519/00
C07D 455/02
C07D 401/14

Abstract:

The present invention relates to compounds of formula I: in which Y, Y, R, Rand Rare defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

US Patent:

20180251471, Sep 6, 2018

Filed:

Jun 15, 2016

Appl. No.:

15/736989

Inventors:

Zhuoliang CHEN - Cambridge MA, US
Jorge Garcia FORTANET - Somerville MA, US
Matthew J. LAMARCHE - Cambridge MA, US
Martin SENDZIK - Cambridge MA, US
Victoriano TAMEZ, JR. - Cambridge MA, US
Bing YU - Cambridge MA, US

International Classification:

C07D 491/107
C07D 401/14
C07D 401/04
A61P 35/00

Abstract:

The present invention relates to compounds of formula I:

US Patent:

20180186770, Jul 5, 2018

Filed:

Jun 15, 2016

Appl. No.:

15/736925

Inventors:

Zhuoliang Chen - Belmont MA, US
Jorge Garcia Fortanet - Wilmington MA, US
Andriana Jouk - Cambridge MA, US
Rajesh Karki - Quincy MA, US
Matthew J. LaMarche - Reading MA, US
Gang Liu - Waltham MA, US
Mark G. Palermo - Rindge NH, US
Lawrence Blas Perez - Silver Spring MD, US
Patrick James Sarver - Princeton NJ, US
Michael David Shultz - Lexington MA, US
Martin Sendzik - Belmont MA, US
Bakary-Barry Toure - Weston MA, US
Bing Yu - Belmont MA, US

International Classification:

C07D 401/14
C07D 491/107
C07D 498/10
C07D 471/10
C07D 401/04

Abstract:

The present invention relates to compounds of formula I:in which Y, Y, Y, R, R, R, R, R, R, Rand Rb are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.